Innovation in Biological Indicator Evaluator Resistometer Vessel Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovation in Biological Indicator Evaluator Resistometer Vessel Technology
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.


Pharmaceutical Technology



Figure 8
Fedegari. During the insertion and removal of the BI cassette, a slight temperature drop in the chamber was recorded. The effect is more pronounced when operating at higher temperatures, but in all cases, the temperature dropped no lower than the set point minus 0.5 °C. The maximum and minimum temperatures recorded during a 121 °C and a 129 °C cycle are displayed in Figure 6. Figure 7 displays the same 121 °C data at a higher resolution. These figures represent the typical performance of the resistometer. Pressure readings in all cycles corresponded with the temperature readings, indicating that saturated steam was present in the chamber.


Table III. Survivor-curve D-values collected in triplicate on spore strip lot S1.


Figure 9
Steris resistometers. Both Steris resistometers operated as described in the ISO standard. The temperature recording from a 121 °C cycle is shown in Figure 8. Fedegari data from Figure 3 also are presented for comparison purposes.


Figure 10
Survivor curve: spore strip. Survivor-curve data collected on the spore-strip lot S1 are shown in Table III. In the Fedegari, D-values were calculated to be 2.7 min in all three trials. In the Steris resistometer, D-values ranged from 2.3 min to 2.8 min (see Figures 9 and 10).


Table IV. Fraction negative D-values collected on spore strip BI lot S1 in three resistometers.
Fraction negative: spore strip. Fraction-negative data collected on the spore strip lot S1 are presented in Table IV. In all three resistometers, D 121-values were 1.5 min.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here